CoChat

Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar I Disorder

Open access
Findling, Robert L., Landbloom, Ronald L., Szegedi, Armin, Koppenhaver, Janelle, Braat, Sabine, Zhu, Qi, Mackle, Mary, Chang, Kiki, Mathews, Maju · 2015 · Journal of the American Academy of Child & Adolescent Psychiatry
Cited by 104

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To evaluate asenapine versus placebo in 403 patients aged 10 to 17 years with bipolar I disorder currently in manic or mixed episodes. METHOD: In this double-blind, placebo-controlled, international trial, patients were randomized 1:1:1:1 to placebo, asenapine 2.5, 5, or 10 mg b.i.d. (twice daily). Primary efficacy measure was change from baseline in Young-Mania Rating Scale (YMRS) total score at day 21. Analyses of patients with/without attention-deficit/hyperactivity disorder (ADHD) and with/without stimulant use were performed. RESULTS: The mean difference in asenapine versus placebo in YMRS was -3.2 (p = .0008), -5.3 (p < .001), and -6.2 (p < .001) for asenapine 2.5, 5, and 10 mg b.i.d., respectively. Treatment-emergent adverse events with an incidence ≥5% and at least twice placebo were somnolence, sedation, hypoesthesia oral, paresthesia oral, and increased appetite. The asenapine groups had a higher incidence of ≥7% weight gain (range, 8.0%-12.0%) versus placebo (1.1%; p < .05). The mean change from baseline in fasting insulin was larger for patients treated with asenapine than those with placebo (asenapine 2.5 mg b.i.d.: 73.375 pmol/L; asenapine 5 mg b.i.d.: 114.042 pmol/L; asenapine 10 mg b.i.d.: 59.846 pmol/L; placebo: 3.690 pmol/L). The mean changes from baseline for lipid parameters and glucose were also larger in asenapine groups than in the placebo group. No safety differences were observed with respect to ADHD and stimulant use. CONCLUSION: All asenapine doses versus placebo were superior based on change in YMRS at day 21. Asenapine was generally well tolerated in patients aged 10 to 17 years with bipolar I disorder in manic or mixed states. Increases in weight and fasting insulin were associated with asenapine. Clinical trial registration information-Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder; http://clinicaltrials.gov; NCT01244815.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaac.2015.09.007

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 24

  1. Perlis, 2009, Retrospective age at onset of bipolar disorder and outcome during two-year follow-up: results from the STEP-BD study, Bipolar Disord, 11, 391, 10.1111/j.1399-5618.2009.00686.x · DOI · Paper page
  2. Birmaher, 2006, Clinical course of children and adolescents with bipolar spectrum disorders, Arch Gen Psychiatry, 63, 175, 10.1001/archpsyc.63.2.175 · DOI · Paper page
  3. Birmaher, 2013, Bipolar disorder in children and adolescents, Child Adolesc Ment Health, 18, 140, 10.1111/camh.12021 · DOI · Paper page
  4. Pavuluri, 2010, Double-blind randomized trial of risperidone vs. divalproex in pediatric bipolar disorder, Bipolar Disord, 12, 593, 10.1111/j.1399-5618.2010.00850.x · DOI
  5. Findling, 2009, Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study, J Clin Psychiatry, 70, 1441, 10.4088/JCP.09m05164yel · DOI · Paper page
  6. Delbello, 2002, A double-blind, randomized, placebo controlled study of quetiapine as adjunctive treatment for adolescent mania, J Am Acad Child Adolesc Psychiatry, 41, 1216, 10.1097/00004583-200210000-00011 · DOI · Paper page
  7. Tohen, 2007, Olanzapine vs. placebo in the treatment of adolescents with bipolar mania, Am J Psychiatry, 164, 1547, 10.1176/appi.ajp.2007.06111932 · DOI · Paper page
  8. Grande, 2014, Antipsychotic switching in bipolar disorders: asystematic review, Int J Neuropsychopharmacol, 17, 497, 10.1017/S1461145713001168 · DOI · Paper page
  9. Dusetzina, 2012, Prevalence of bipolar disorder diagnoses and psychotropic drug therapy among privately insured children and adolescents, Pharmacother, 32, 1085, 10.1002/phar.1148 · DOI
  10. Kowatch, 2005, Treatment guidelines for children and adolescents with bipolar disorder, J Am Acad Child Adolesc Psychiatry, 44, 213, 10.1097/00004583-200503000-00006 · DOI · Paper page
  11. Costall, 1990, Actions of ORG 5222 as a novel psychotropic agent, Pharmacol Biochem Behav, 35, 607, 10.1016/0091-3057(90)90298-V · doi:10.1016/0091-3057(90)90298-v
  12. McIntyre, 2010, Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder, Expert Rev Neurother, 10, 645, 10.1586/ern.10.49 · DOI
  13. Tarazi, 2013, The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania, Expert Opin Drug Discov, 8, 93, 10.1517/17460441.2013.738193 · DOI
  14. Shahid, 2009, Asenapine: a novel psychopharmacologic agent with a unique human receptor signature, J Psychopharmacol, 23, 65, 10.1177/0269881107082944 · DOI · Paper page
  15. McIntyre, 2009, A 3-week, randomized, PBO-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states, Bipolar Disord, 11, 673, 10.1111/j.1399-5618.2009.00748.x · DOI · Paper page
  16. McIntyre, 2010, Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, PBO-controlled trial, J Affect Disord, 122, 27, 10.1016/j.jad.2009.12.028 · DOI · Paper page
  17. Haas, 2009, Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study, Bipolar Disord, 11, 687, 10.1111/j.1399-5618.2009.00750.x · DOI · Paper page
  18. Firstad, 1992, The Mania Rating Scale: can it be used in children? A preliminary report, J Am Acad Child Adolesc Psychiatry, 31, 252, 10.1097/00004583-199203000-00011 · DOI · Paper page
  19. Youngstrom, 2002, Factor structure for the young mania rating scale for use with youths ages 5 to 17 years, J Clin Child Adolesc Psychol, 31, 567, 10.1207/S15374424JCCP3104_15 · doi:10.1207/s15374424jccp3104_15 · Paper page
  20. Poznanski, 1979, A depression rating scale for children, Pediatrics, 64, 441, 10.1542/peds.64.4.442 · DOI · Paper page
  21. Poznanski, 1985, Diagnostic criteria in childhood depression, Am J Psychiatry, 142, 1168, 10.1176/ajp.142.10.1168 · DOI · Paper page
  22. Jain, 2007, A psychometric evaluation of the CDRS and MADRS in assessing depressive symptoms in children, J Am Acad Child Adolesc Psychiatry, 46, 1204, 10.1097/chi.0b013e3180cc2575 · DOI
  23. Chouinard, 2005, Manual for the Extrapyramidal Symptom Rating Scale (ESRS), Schizophrenia Res, 76, 247, 10.1016/j.schres.2005.02.013 · DOI · Paper page
  24. Mietinnen, 1985, Comparative analysis of two rates, Stat Med, 4, 213, 10.1002/sim.4780040211 · DOI · Paper page

Cited by

See all 104

Metadata

Authors
Findling, R. L., Landbloom, R. L., Szegedi, A., Koppenhaver, J., Braat, S., Zhu, Q., Mackle, M., Chang, K., & Mathews, M.
Venue
Journal of the American Academy of Child & Adolescent Psychiatry
Publisher
Elsevier BV
Published
2015-12
Volume
54
Issue
12
Pages
1032-1041
ISSN
0890-8567 (ISSN-L)
OpenAlex
W1859959435
Cited by
104
References
7
FWCI
9.17
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.